Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotech company focused on developing targeted and immune-mediated cancer therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Dr. Sam Whiting, the company's chief medical officer and head of R&D, will deliver a presentation that will be available for on-demand viewing starting September 9, 2024, at 7:00 a.m. ET.
Investors and interested parties can access the presentation through the investor section of Tempest's website. This event provides an opportunity for Tempest to showcase its innovative approach to cancer treatment and potentially attract investor interest in its clinical-stage pipeline.
Tempest Therapeutics (Nasdaq: TPST), un'azienda biotech in fase clinica dedicata allo sviluppo di terapie oncologiche mirate e mediate dal sistema immunitario, ha annunciato la sua partecipazione alla 26esima Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. Il Dr. Sam Whiting, direttore medico dell'azienda e responsabile della R&D, presenterà una relazione disponibile per visione on-demand a partire dal 9 settembre 2024, alle 7:00 a.m. ET.
Gli investitori e le parti interessate possono accedere alla presentazione tramite la sezione investitori del sito web di Tempest. Questo evento offre a Tempest l'opportunità di mostrare il suo approccio innovativo al trattamento del cancro e di attirare potenzialmente l'interesse degli investitori per il suo pipeline in fase clinica.
Tempest Therapeutics (Nasdaq: TPST), una compañía biotecnológica en etapa clínica centrada en el desarrollo de terapias contra el cáncer dirigidas y mediadas por el sistema inmunológico, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversores H.C. Wainwright. El Dr. Sam Whiting, director médico de la compañía y jefe de I+D, realizará una presentación que estará disponible para visualización bajo demanda a partir del 9 de septiembre de 2024, a las 7:00 a.m. ET.
Los inversores y partes interesadas pueden acceder a la presentación a través de la sección de inversores del sitio web de Tempest. Este evento brinda a Tempest la oportunidad de mostrar su enfoque innovador en el tratamiento del cáncer y potencialmente atraer el interés de los inversores en su pipeline en etapa clínica.
템페스트 테라퓨틱스 (Nasdaq: TPST)는 타겟 및 면역 매개 암 치료제 개발에 중점을 둔 임상 단계의 생명공학 회사로, H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 샘 화이팅 박사가 회사의 최고 의학 책임자이자 R&D 책임자로서 2024년 9월 9일 오전 7시 ET부터 온디맨드로 시청 가능한 발표를 진행할 예정입니다.
투자자 및 관심 있는 당사자들은 템페스트 웹사이트의 투자자 섹션을 통해 발표에 접근할 수 있습니다. 이 이벤트는 템페스트가 암 치료에 대한 혁신적인 접근 방식을 선보이고, 임상 단계 파이프라인에 대한 투자자 관심을 끌 수 있는 기회를 제공합니다.
Tempest Therapeutics (Nasdaq: TPST), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies anticancéreuses ciblées et médiées par le système immunitaire, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Le Dr. Sam Whiting, directeur médical de l'entreprise et responsable de la R&D, fera une présentation disponible pour visionnage à la demande à partir du 9 septembre 2024, à 7h00 ET.
Les investisseurs et les parties intéressées peuvent accéder à la présentation via la section investisseurs du site web de Tempest. Cet événement offre à Tempest l'opportunité de présenter son approche innovante en matière de traitement du cancer et de potentiellement attirer l'intérêt des investisseurs pour son pipeline en phase clinique.
Tempest Therapeutics (Nasdaq: TPST), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von gezielten und immunvermittelten Krebstherapien konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Dr. Sam Whiting, der Chief Medical Officer des Unternehmens und Leiter der Forschung und Entwicklung, wird eine Präsentation halten, die ab dem 9. September 2024 um 7:00 Uhr ET auf Abruf verfügbar sein wird.
Investoren und Interessierte können die Präsentation über den Investorenbereich der Website von Tempest abrufen. Diese Veranstaltung bietet Tempest die Möglichkeit, ihren innovativen Ansatz zur Krebsbehandlung zu präsentieren und möglicherweise das Interesse von Investoren an ihrer klinischen Pipeline zu wecken.
- None.
- None.
BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest, will present at the H.C. Wainwright 26th Annual Global Investment Conference.
The company presentation will be available for on-demand viewing Monday, September 9, 2024, at 7:00 a.m. ET on the investor section of the Tempest website at https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor & Media Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
—————————————————
i If approved by the FDA
FAQ
When is Tempest Therapeutics (TPST) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Tempest Therapeutics (TPST) at the investment conference?
Where can investors view Tempest Therapeutics' (TPST) presentation from the conference?
What is the focus of Tempest Therapeutics' (TPST) research and development?
